Understanding how long COVID-19 can persist after recovery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the persistence of SARS-CoV-2 in individuals who have recovered from COVID-19. It will enroll 325 participants with confirmed COVID-19 diagnoses and 25 negative controls to analyze how long the virus can remain in various body fluids and how quickly antibodies develop. Participants will complete surveys and provide biological samples over a 24-month period to assess post-infectious complications and viral persistence. The study will utilize a combination of laboratory testing and participant-reported data to gather comprehensive insights.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Laboratory confirmed SARS-CoV-2 using currently available laboratory testing techniques (e.g.,RT-PCR, Immunoglobulin M (IgM) /IgG) or clinical history compatible with a COVID-19 like illness(fever, cough, shortness of breath).
* Negative participants with no known prior COVID-19 diagnosis or COVID vaccine
* At least 7 years of age
* Participants are eligible to provide semen and breast milk samples if they are 18 years of age or older

Exclusion Criteria:

* Age \<7
* Intercurrent conditions that in the opinion of the investigator would confound the findings of the study.

Where it's running

• Columbia University Medical Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Michael Yin, MD, MS — Associate Professor of Medicine
• Study coordinator: Michael Yin, MD, MS
• Email: mty4@cumc.columbia.edu
• Phone: 212-305-7185

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Vaccine formulations containing mRNA-1273 and mRNA-1283 to see if they boost immunity and remain safe

  This study tests whether two mRNA vaccines that target SARS-CoV-2 can safely generate an immune response in older adults and people with risk factors.

  Recruiting at 5 sites Phase 4 ModernaTX, Inc. · Overland Park, Kansas and 4 other locations · NCT07863635

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Vaccine study to test mRNA-1283 in children and infants

  A vaccine study will test two dose levels of mRNA-1283 in kids from 6 months to under 12 years to see which dose works best, using mRNA-1273 as a comparison.

  Recruiting at 12 sites Phase 2 ModernaTX, Inc. · Ontario, California and 30 other locations · NCT07808697

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Secutrelvir for high-risk COVID-19 patients who are not in hospital

  This study tests whether secutrelvir can help nonhospitalized teens and adults with COVID-19 who are at high risk of getting worse.

  Recruiting at 38 sites Phase 3 Shionogi Inc. · Coral Gables, Florida and 50 other locations · NCT07743580

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.